Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis Achieves Ophthalmology Milestone With Korean Aflibercept Approval

SB15 Biosimilar To Eylea Approved Shortly After Firm Agreed Marketing Deal With Samil

Executive Summary

Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.

You may also be interested in...



Samsung Bioepis And Sandoz Get EU Nod For Stelara Rival

Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.

A $31bn Opportunity? Future Of Biosimilars Inches Closer With Samsung Keytruda Study

Samsung Bioepis is among a small pool of players heading to the clinic for a proposed biosimilar to Merck & Co’s PD-1 mega-blockbuster, as interest and investment rises ahead of patent expiry at the end of the decade.

FDA Approves First Ophthalmic Biosimilar With Samsung Bioepis’ Lucentis Rival

Samsung Bioepis has celebrated the FDA’s first ever approval of an ophthalmic biosimilar with its endorsement of the firm’s Byooviz ranibizumab rival to Lucentis. The firm has also signaled a surprising expected launch date in the US, as well as offering expectations for launch in Europe where the biosimilar was also recently approved.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel